BRPI1009616A2 - diferentes sorotipos de vírus da estomatite vesicular como vetores de expressão para regimes de imunização - Google Patents

diferentes sorotipos de vírus da estomatite vesicular como vetores de expressão para regimes de imunização

Info

Publication number
BRPI1009616A2
BRPI1009616A2 BRPI1009616A BRPI1009616A BRPI1009616A2 BR PI1009616 A2 BRPI1009616 A2 BR PI1009616A2 BR PI1009616 A BRPI1009616 A BR PI1009616A BR PI1009616 A BRPI1009616 A BR PI1009616A BR PI1009616 A2 BRPI1009616 A2 BR PI1009616A2
Authority
BR
Brazil
Prior art keywords
immunization
vesicular stomatitis
stomatitis virus
expression vectors
serotype
Prior art date
Application number
BRPI1009616A
Other languages
English (en)
Inventor
Kang Chil-Young
Nyoun Kim Gyuong
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Publication of BRPI1009616A2 publication Critical patent/BRPI1009616A2/pt
Publication of BRPI1009616B1 publication Critical patent/BRPI1009616B1/pt
Publication of BRPI1009616B8 publication Critical patent/BRPI1009616B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/12043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

diferentes sorotipos de virus da estomatite vesicular como vetores de expressão para regimes de imunização plataformas de imunização, regimes de vacinação e medicamentos úteis para induzir uma resposta imune em um mamífero e prevenir ou tratar uma infecção patogênica em um mamífero, em que as ditas plataformas de imunização e medicamentos constituem um vírus recombinante da estomatite vesicular (vsv) de um sorotipo e um rvsv de outro sorotipo e são utilizados em regime de imunização primeboost. em aspectos da invenção um sorotipo vsv é indiana e o outro sorotipo vsv é new jersey.
BRPI1009616A 2009-06-08 2010-06-08 plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit BRPI1009616B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18495909P 2009-06-08 2009-06-08
US61/184,959 2009-06-08
PCT/CA2010/000874 WO2010142030A1 (en) 2009-06-08 2010-06-08 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens

Publications (3)

Publication Number Publication Date
BRPI1009616A2 true BRPI1009616A2 (pt) 2019-07-16
BRPI1009616B1 BRPI1009616B1 (pt) 2021-05-11
BRPI1009616B8 BRPI1009616B8 (pt) 2021-05-25

Family

ID=43308343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009616A BRPI1009616B8 (pt) 2009-06-08 2010-06-08 plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit

Country Status (9)

Country Link
US (1) US9248178B2 (pt)
EP (1) EP2440244B1 (pt)
JP (1) JP5675789B2 (pt)
KR (1) KR101723900B1 (pt)
AU (1) AU2010258047B2 (pt)
BR (1) BRPI1009616B8 (pt)
CA (1) CA2764903C (pt)
ES (1) ES2533345T3 (pt)
WO (1) WO2010142030A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943593B2 (en) 2013-06-26 2018-04-17 The University Of Western Ontario Modified matrix proteins of vesicular stomatitis virus
AU2015225553B2 (en) * 2014-03-01 2020-02-27 Profectus Biosciences, Inc. Recombinant Isfahan viral vectors
WO2021207848A1 (en) * 2020-04-16 2021-10-21 Sumagen Canada Inc. Mers-cov vaccine
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
KR20230156918A (ko) * 2021-03-03 2023-11-15 스마젠 캐나다 인크. 재조합 vsv-sars-cov-2 백신
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
WO2025208054A1 (en) 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527087B2 (en) * 2002-07-26 2013-07-17 Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
ATE468859T1 (de) * 2003-03-26 2010-06-15 Wyeth Llc Immunogene zusammensetzung und verfahren
ATE539162T1 (de) * 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein

Also Published As

Publication number Publication date
WO2010142030A1 (en) 2010-12-16
JP2012529427A (ja) 2012-11-22
US20120100176A1 (en) 2012-04-26
KR101723900B1 (ko) 2017-04-07
BRPI1009616B8 (pt) 2021-05-25
EP2440244A1 (en) 2012-04-18
AU2010258047A1 (en) 2011-12-22
WO2010142030A8 (en) 2011-12-29
JP5675789B2 (ja) 2015-02-25
EP2440244A4 (en) 2013-05-29
US9248178B2 (en) 2016-02-02
CA2764903C (en) 2017-10-31
EP2440244B1 (en) 2015-01-28
ES2533345T3 (es) 2015-04-09
AU2010258047B2 (en) 2016-01-14
BRPI1009616B1 (pt) 2021-05-11
KR20120032486A (ko) 2012-04-05
CA2764903A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
BRPI1009616B8 (pt) plataforma de imunização para uso em uma estratégia de imunização prime-boost e kit
CY1124288T1 (el) Cmv εμβολια
BR112017016417A2 (pt) moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
UY33797A (es) Composiciones farmacéuticas para el tratamiento del vhc
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
MX2013007211A (es) Circovirus porcino tipo 2 (pcv2), composicion inmunogenica que contiene el mismo, equipo de prueba y aplicacion del mismo.
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
CL2008000611A1 (es) Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
BRPI0923341B8 (pt) oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
BR112013030963A2 (pt) proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira ou organismo, composição farmacêutica ou vacina, uso da proteína de fusão, método para prevenir ou tratar infecção hev ou doenças associadas com infecção hev, método para prevenir ou tratar infecção do vírus influenza e doenças associadas com a infecção do vírus influenza, método para melhorar a imunogenicidade de uma proteína alvo e uso de crm197 ou um fragmento do mesmo
BRPI0909123A2 (pt) anticorpos monoclonais capazes de reagir com uma pluralidade de subtipos de vírus de influenza a
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
NO20090194L (no) Rekombinant viral vaksine
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
BR112018010679A2 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
EA201791401A1 (ru) СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЁННОГО КИШЕЧНИКА С ПРЕОБЛАДАНИЕМ ДИАРЕИ С ПРИМЕНЕНИЕМ Bacillus coagulans SBC37-01, MTCC 5856

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.